Polycystin-1 (PC1) is a highly conserved, receptor-like multi-domain membrane protein widely expressed in various cell types and tissues (1, 2) . Mutations of human PKD1 cause Autosomal Dominant Polycystic Kidney Disease (ADPKD) (3, 4) . The genetics of ADPKD is complex, since it is widely held that inactivation of the normal copy of the PKD1 gene by a second somatic mutation in conjunction with the inherited mutation of the other allele are required for renal cyst formation, which occurs in only a subset of the dually affected tubules (5) . Although primarily affecting the kidney, ADPKD is also a multisystem disorder (6, 7) . Extrarenal manifestations include intracranial and aortic aneurysms, and cystic disease of liver and pancreas (8) (9) (10) (11) . The biological functions of PC1 are poorly defined in some tissues that express PKD1 transcripts, such as bone. Indeed, the absence of clinically demonstrable skeletal abnormalities in patients with ADPKD initially delayed the investigation of PKD1 function in bone. The apparent lack of abnormalities in other tissues expressing PC1 may arise because of differences in the frequency of a second hit somatic mutation, the presence of other modifying factors that may compensate for lack of PC1 function in other organs (12) , or failure to detect more subtitle phenotypes. For example, lung was not thought to be affected by PKD1 mutations until CT scans of lungs of ADPKD patients showed a 3-fold increase in the prevalence of bronchiectasis compared to controls (13) .
Pkd1 is highly expressed in bone and several mouse models with inactivating mutations of Pkd1 have skeletal abnormalities in the setting of polycystic kidney disease and embryonic lethality (6, 7, (14) (15) (16) . Most recently, however, the heterozygous Pkd1 m1Bei mouse, which has an inactivating mutation of Pkd1 and survives to adulthood without polycystic kidney disease, has been shown to develop osteopenia and impaired osteoblastic differentiation (17, 18) , suggesting that Pkd1 may function in bone. Since homozygous PKD1/Pkd1 mutations in humans and mice are lethal, and most of the existing models are globally Pkd1 deficient, the significance of inactivation of Pkd1 in osetoblasts remains uncertain, and the bone changes might reflect an indirect effect due to loss of PKD1/Pkd1 in the kidney or other tissues.
In the current study, to determine if Pkd1 in osteoblasts has a direct function in regulating postnatal skeletal functions, we used mouse genetic approaches to conditionally delete Pkd1 in osteoblasts. We demonstrate that conditional deletion of Pkd1 from osteoblasts of heterozogyous Pkd1 m1Bei/+ mutant mice in defective osteoblast-function in vivo and in vitro, and osteopenia, indicating that Pkd1 has a direct role to regulate osteoblast function and skeletal homeostasis.
EXPERIMENTAL PROCEDURES
Mice -We obtained the floxed Pkd1 mice from Dr. Gregory Germino at Johns Hopkins University (19) and Osteocalcin (Oc)-Cre mice from Dr. Thomas Clemens at University of Alabama (20) . The Pkd1 m1Bei heterozygous mice were available in our laboratory as previously described (18) . These mice were bred and maintained on a C57BL/6J background. At first, we created double heterozygous Oc-Cre;Pkd1 m1Bei/+ mice and homozygous Pkd1 flox/flox mice. Then double heterozygous OcCre;Pkd1 m1Bei/+ mice were mated with homozygous , equivalent to wildtype). These mice were used for phenotypic analysis. Animal experiments were performed following review and approval by University of Kansas Medical Center's Animal Care and Use Committee.
Genotyping PCR and real-time PCR to detect mutations and deletions -Genomic DNA was prepared from bone and other tissue specimens using standard procedures. PCR genotyping was performed using the following primers (19) (Fig 1A) : F1, 5'-CTT CTA TCG CCT TCT TGA CGA GTT C-3'; R1, 5'-AGG GCT TTT CTT GCT GGT CT-3'; R2, 5'-TCG TGT TCC CTT ACC AAC CCT C-3'. Pkd1 floxed (Pkd1 flox ) alleles were identified in 2% agarose gels as 670-bp bands (Fig 1B) . The delta floxed Pkd1 (Pkd1 Δflox ) allele was detected as a 0.85-kb band in 1% agarose gels (Fig 1B) . The Pkd1 m1Bei allele was genotyped using SYBR ® Green (Bio-Rad) real-time PCR as previously described (18) .
Bone Densitometry, histomorphometric and Micro-CT analysis -Bone mineral density (BMD) of femurs was assessed at 16 weeks of age using a LUNAR PIXIMUS bone densitometer (Lunar Corp, Madison, WI). Calcein (Sigma, St. Louise, MO) double labeling of bone and histomorphometric analyses of periosteal mineral apposition rate (MAR), mineralized surface per bone surface (MS/BS), and bone formation rate (BFR) in tibias were performed using the osteomeasure analysis system (Osteometrics). Goldner and Von Kossa staining were performed according to standard protocols (21, 22) . The distal femoral metaphyses were also scanned using a Scanco CT 40 (Scanco Medical AG, Brüttisellen, Switzerland). A 3D images analysis was done to determine bone volume (BV/TV) and cortical thickness (Ct.Th) as previously described (18, 21) .
Detection of bone marrow adipocytes in long bones by oil red O lipid staining -Whole intact femurs with encapsulated marrow were dissected from 18 weeks old mice, fixed for 48 hours in phosphate buffered paraformaldehyde, decalcified in 14% EDTA and then embedded in tissue freezing medium. Cryosectioning was performed on a Leica CM1900 Cryostat (Leica, Nussloch, Germany) equipped with a CryoJane frozen sectioning kit (Instrumedics, Hackensack, NJ). 10 m thick sections were then stained with oil red O (ORO) for bone marrow adipocytes as described before (23) . Briefly, the sections were rinsed in 60% isopropanol, stained for 20 minutes in 0.5% ORO-isopropanol solution, differentiated in 60% isopropanol, rinsed in tap water and mounted in glycerin jelly. Sections were examined with a Leica DM LB microscope equipped with an Optronics digital camera.
Detection of bone marrow fat in long bones by Micro-CT -Whole intact tibiae with encapsulated marrow were dissected from 18 weeks old mice, fixed for 48 hours in phosphate buffered paraformaldehyde, decalcified in 14% EDTA and stained for 2 hours in 2% aqueous osmium tetroxide (OsO4). Bones were rinsed in water for 48 hours and then scanned at 6 m resolution using a Scanco μCT40, 45 KeVp and 177 A. Quantification of fat volume, density, and distribution throughout the marrow was registered to low contrast decalcified bone.
Real-time RT-PCR -For quantitative realtime RTPCR, 2.0 g total RNA isolated from either the long bone of 16-week-old mice or 10-days cultured primary osteoblasts in differentiation media was reverse transcribed as previously described (24) . PCR reactions contained 100 g template (cDNA or RNA), 300 M each forward and reverse primers, and 1X iQ TM SYBR  Green Supermix (Bio-Rad, Hercules, CA) in 50 l. The threshold cycle (Ct) of tested-gene product from the indicated genotype was normalized to the Ct for cyclophilin A. Expression of total Pkd1 transcripts was performed using the following Pkd1-allele-specific primers: In exon 26, forward primer of normal Pkd1 + transcript: 5'-CTG GTG ACC TAT GTG GTC AT -3', forward primer of mutant Pkd1 m1Bei transcript: 5' -CTG GTG ACC TAT GTG GTC AG -3', and common reverse primer: 5' -AGC CGG TCT TAA CAA GTA TTT C -3'. In exon 2-4, forward primer of normal Pkd1 + vs cyclophilin A is normalized to the mean ratio of 5 control mice, which has been set to 1. The percentage of conditional deleted and mutant transcripts was calculated from the relative levels of the normal Pkd1 + transcripts in different Pkd1 exons (25) . Serum Biochemistry-Serum osteocalcin levels were measured using a mouse osteocalcin EIA kit (Biomedical Technologies Inc. Stoughton, MA, USA). Serum urea nitrogen (BUN) was determined using a BUN diagnostic kit from Pointe Scientific, Inc. Serum calcium (Ca) was measured by the colorimetric cresolphthalein binding method, and phosphorus (P) was measured by the phosphomolybdateascorbic acid method (Stanbio Laboratory, TX, USA). Serum TRAP was assayed with the ELISAbased SBA Sciences mouseTRAP TM assay (Immunodiagnostic Systems, Fountain Hills, AZ).
Primary osteoblast culture for proliferation, differentiation, and western blot analysis -Primary osteoblasts from newborn mouse calvarias were cultured in -MEM containing 10% FBS and 1% P/S as previously described (24) . Cell proliferation was detected by BrdU incorporation assays as the manufacturer describes (QIA58, Calbiochem, Gibbstown, NJ). To induce differentiation, primary osteoblasts were plated at a density of 1x 10 5 cells per well in a 6-well plate, and grown for period of up to 21 days in -MEM containing 10% FBS supplemented with 5 mM -glyceropho-phate and 25 g/ml of ascorbic acid. Alkaline phosphatase activity and Alizarin red-S histochemical staining for mineralization were performed as previously described (24) . Total DNA content was measured with a PicoGreen  dsDNA quantitation reagent and kit (Molecular Probes, Eugene, OR).
To examine the amounts of cytoplasmic Akt, Gsk, and β-catenin, the cells were prepared using 1x Passive Lysis Buffer for 30 minutes at 4 C (Promega, Madison, WI) and centrifuged at 100,000g for 45 minutes at 4 C. Protein concentrations of the supernatant were determined with a BioRad protein assay kit (Bio-Rad, Hercules, CA). Equal quantities of protein were subjected to Nu-PAGE TM 4-12% Bis-Tris Gel (Invitrogen, Carlsbad, CA) and were analyzed with standard Western blot protocols (HRP-conjugated secondary antibodies from Santa Cruz Biotechnology and ECL from Amersham Biosciences, Buckinghamshire, UK). Antibodies against phospho-Akt (ser-473), Akt, phospho-GSK (ser9), GSK were from Cell Signaling Technology (Beverly, MA). Anti-β-catenin (sc-7199) and Anti-β-actin (sc-47778) antibodies were from Santa Cruz Biotechnology.
Transient transfection -Both MC3T3-E1 and primary osteoblasts were cultured in -MEM containing 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (P/S). To examine if PC1 regulates Runx2-P1 promoter activity by coupling with PI3K-Akt signaling, a number of 1 x 10 6 of MC3T3-E1 cells were transfected with either control expression vector (sIg) or gain-of-function PC1 Ctail construct (PC1-AT) along with the Runx2-P1 luciferase reporter (p0.42Runx2-P1-Luc) construct by electroporation using Cell Line Nucleofector Kit R according to the manufacturer's protocol (Amaxa Inc, Gaithersburg, MD). A total of 10.2 g of plasmid DNA was used for each electroporation, with 3.6 g of PC1 C-tail construct, 2.4 g of p0.42Runx2-P1-Luc reporter, the indicated amounts of a dominant-negative Akt (dn-Akt) construct in combination with empty vector (3.6 g), and 0.6 g of Renilla luciferase-null (RL-null) as internal control plasmid. Promoter activity was assessed by measuring luciferase activity 48 hours after transfection in the presence or absence of a PI3K inhibitor (0.1~10 M, LY294002) and a dn-Akt construct (1.2~3.6 µg) as previously described (17, 18) .
To explore potential abnormalities of the Wnt pathway in excised floxed Pkd1 null mice, control (Pkd1 flox/+ ) and excised floxed Pkd1 null (Pkd1 Oc-cko ) osteoblasts were transiently cotransfected with either pTOPFLASH or pFOPFLASH along with Renilla luciferase-null (RL-null, Promega, Madison, WI) as an internal control as described above. Promoter activity will be assessed by measuring luciferase activity 48 hours after transfection in the presence or absence of 100 ng/ml of recombinant Wnt3a treatment for last 8 hours.
Statistics -We evaluated differences between groups by one-way analysis of variance. All values are expressed as means ± S.D. All computations were performed using the GraphPad Prism5 (GraphPad Software Inc. La Jolla, CA). , and Pkd1 flox/+ ) were born at the expected Mendelian frequency and all exhibited survival indistinguishable from wild-type mice.
RESULTS

Oc-Cre mediated bone-specific deletion of
The normal survival of conditional Pkd1
Oc-cKO null mice (Oc-Cre;Pkd1
) contrasts with perinatal lethality of homozygous Pkd1 m1Bei/m1Bei mice (17) . Oc-Cre expression is limited to cells of the osteoblast lineage (late osteoblasts>osteocytes) with onset of expression just before birth and persisting throughout the mature osteoblast lineage (20) . To confirm that the Pkd1 floxed allele was selectively deleted in bone, we performed PCR analysis using a combination of primers that specifically detect floxed Pkd1 alleles (Pkd1 flox ) and the excised floxed Pkd1 alleles (Pkd1
flox/m1Bei mice, (Fig. 1A) . We demonstrated that Oc-Cre-mediated floxed recombination occurred exclusively in tissues that contain osteoblastic cells, whereas non-skeletal tissues retained the intact floxed Pkd1 alleles (Pkd1 flox ) (Fig. 1B) . The Pkd1 m1Bei mutation, which functions as a null allele, was used in combination with the floxed Pkd1 allele (Pkd1 flox ) to increase the net efficiency of Pkd1 inactivation by Cre-recombinase to reduce functional Pkd1 expression. Therefore, we examined the percentage of Pkd1 conditional deleted and the Pkd1 m1Bei mutant alleles in bone. The level of conditional deleted Pkd1
Δflox alleles and the presence of the Pkd1 m1Bei mutation from the femurs of these four genotypes mice were assessed by real time PCR (Fig. 1C) Δflox allele and mutant Pkd1 m1Bei allele demonstrated no cyst formation in the kidney, consistent with the bone specific inactivation of Pkd1 (Fig 1D) . In contrast, positive control mice lacking Pkd1 in the kidney have massive cyst formation in the kidney (Fig 1D) . ), however, were osteopenic, as evidenced by respective 9% and 7% reduction BMD in both male and female adult mice ( Fig. 2A) . The phenotype of the Pkd1
Oc-cKO mice was more severe. The body weight of both male and female Pkd1
Oc-cKO mice was reduced by approximately 16% and 12% (data not shown) compared to the control mice (Pkd1 flox/+ ). In addition, Pkd1
Oc-cKO mice had greater loss in BMD, with respective reductions in BMD of 14% and 13% reduction in male and female adult mice ( Fig. 2A) . The abnormalities in BMD in the various groups, though present at 6 weeks of age, segregated by gene-dose by 16 weeks of age ( Fig  2B) .
CT analysis revealed that the reduction in bone mass in heterozygous Pkd1 deficient mice (either Pkd1 flox/m1Bei or Oc-Cre;Pkd1
) was caused by a reduction in trabecular bone volume (24.3% and 25.5%, respectively) and cortical bone thickness (9.7% and 10.8%, respectively) (Fig. 2C) . Pkd1 cKO/m1Bei had greater loss in both trabecular (44.5%) and cortical bone (21.0%) than did single heterozygous mice (Fig. 2C ).
Consistent with a low-bone-mass phenotype by BMD and CT analysis, both Goldner staining in distal femur and Von Kossa staining in vertebrae confirmed marked reductions in bone volume and cortical thickness in Pkd1
Oc-cKO null mice (Fig. 3A) . In addition, we found that bone loss was associated with a significant Pkd1 gene dose-dependent decrease in periosteal mineral apposition rate (MAR), mineralized surface per bone surface (MS/BS), and bone formation rate (BFR). In this regard, MAR, MS/BS, and BFR were reduced by ~36%, ~33%, and ~57% in heterozygous Pkd1 flox/m1Bei and OcCre;Pkd1 flox/+ mice and ~65%, ~60%, and ~87% in Pkd1
Oc-cKO null mice compared with age-matched controls, respectively (Fig. 3B) .
To investigate the effects of Pkd1 deficiency on gene expression profiles in bone, we examined by real-time RT-PCR the expression levels of a panel of osteoblast lineage-, osteoclast-, and chondrocyterelated mRNAs from the femurs of 16- Oc-cKO null mice. In this regard, the Opg/RankL expression ratio was increased in a gene dose-dependent manner (Table I) . Consistent with a ratio of Opg/RankL that favors the reduced osteoclastogenesis, bone expression of Trap and Mmp9, markers of bone resorption, were also reduced in heterozygous Pkd1 deficient mice and to a greater extent in Pkd1
Oc-cKO null mice (Table I) . Transcripts of chondrocyte-related genes did not differ between heterozygous Pkd1 deficient and Pkd1
Oc-cKO null mice (Table I) . Changes in gene expression in bone correlated with alterations in serum biomarkers. In this regard, further evidence for osteoblast dysfunction includes a reduction in Osteocalcin in serum from 16-week-old heterozygous Oc-Cre;Pkd1 flox/+ and Pkd1 m1Bei/+ mice (Table II) . Serum levels of TRAP, a marker of bone resorption, were also reduced in heterozygous Pkd1-deficient mice compared to control littermates (Table II) . As with other parameters,
Pkd1
Oc-cKO null mice had greater reductions in bone formation and resorption markers, indicating additive effects of inactivation of both Pkd1 alleles in bone homeostasis. Collectively, these findings suggest that Pkd1-mediated bone loss results from low bone formation rates rather than increased bone resorption (Fig. 2, A-C , Table II) .
PPAR, an adipocyte transcription factor, and adipocyte markers, including lipoprotein lipase (Lpl) and adipocyte fatty acid-binding protein 2 (aP2) were increased femurs of Pkd1 deficient mice in a Pkd1 gene dosage-related manner (Table I) . Consistent with increased adipogenic markers, bone marrow exhibited an increased percentage of fat cells in Pkd1
Oc-cKO mice, as evidenced by a higher number of adipocytes and volume of fat droplets in decalcified femurs and tibias stained with Oil Red O and Osmium tetroxide (OsO4) (Fig 3C) . In addition, the inflammatory cytokine IFN, but not TNFα and TRAIL expression levels, was significantly elevated in Pkd1 deficient mice (Table I) . Moreover, Alox15, arachidonate 15-lipoxygenase, was also markedly increased in conditional Pkd1 deficitn mice.
Effect of conditional deletion Pkd1 on osteoblastic function ex vivo -To determine the impact of conditional deleted Pkd1 on osteoblast function ex vivo, we examined cell proliferation and osteoblastic differentiation and gene expression profiles in primary osteoblast cultures derived from control and Pkd1
Oc-cKO null mice. Consistent with defects in bone formation, we found that Pkd1
Oc-cKO null osteoblasts had a higher BrdU incorporation than control osteoblasts, indicating a greater proliferation rate in Pkd1
Oc-cKO null osteoblasts (Fig. 4A ). In addition, conditional null osteoblasts displayed impaired osteoblastic differentiation and maturation, as evidenced by lower alkaline phosphatase activity, diminished calcium deposition in extracellular matrix, and reduced osteoblastic differentiation markers compared to controls (Fig. 4B-4D ). In agreement with increased adipogenic activity in vivo, the cultured primary calvarial cells under osteogenic condition exhibited a markedly increase of adipocyte markers, including PPAR, aP2, and Lpl (Fig. 4E) , suggesting impairment of osteogenesis and enhancement of adipogenesis in Pkd1
Oc-cKO null osteoblast cultures.
Effect of conditional deletion Pkd1 on PI3K-Akt-Gsk--catenin signaling pathway in osteoblasts. PC1 encoded by Pkd1 is coupled to multiple signal transduction pathways, including activation of canonical Wnt/catenin and Akt-dependent pathways. There is evidence Akt-dependent serine 9 phosphorylation of GSK-3β that prevents phosphorylation and degradation of β-catenin (26) (27) (28) (29) . Because the phosphatidylinositol 2-kinase (PI3-kinase)/Akt pathway and Wnt signaling play a role in osteoblastic development (30, 31) , we determined the level of Akt phosphorylation in Pkd1
Oc-cKO derived osteoblasts. Basal phospho-Akt relative to total Akt expression and phosphorylation of serine 9 of GSK-3β were reduced in Pkd1
Oc-cKO null osteoblasts compared to controls. To determine if potential cross-talk between PC1/PI3K/Akt pathway and the Wnt/GSK3catenin pathways have functional consequences (28), we next examined the response of osteoblasts derived from Pkd1
Oc-cKO mice to Wnt3a. Pkd1
Oc-cKO derived osteoblasts had a reduced response to Wnt3a-mediated phosphorylation of Akt when compared to control cells (Fig. 5A) . In contrast, addition of Wnt3a resulted in an increase in phosphorylation of GSK3 in control cells, leading to the inactivation of GSK3 (Fig. 5A) . To determine if inhibition of GSK3 activated -catenin (32), we assessed the accumulation of free -catenin in the cytoplasm (33) . Consistent with reduction of GSK3 phosphorylation, we found that the basal level of cytosolic -catenin was lower in Pkd1
Oc-cKO null osteoblasts and exhibited no increase following Wnt3a treatment, whereas control cells increased cytoplasmic -catenin levels following Wnt3a stimulation (Fig. 5A) .
To examine the effect of Pkd1 inactivation on Wnt/-catenin transcriptional activity, we examined TOPFlash activity in Pkd1
Oc-cKO null osteoblasts. We observed a significant reduction of basal TOPFLASH activity in primary osteoblasts derived from Pkd1
Oc-cko mice compared to the controls. In addition, Wnt3a-induced TOPFLASH activity was more than 2-fold above basal level in the control osteoblasts, whereas Wnt3a induced TOPFLASH activity was only 1.4-fold above basal level in the Pkd1
Oc-cKO null mice (Fig. 5B) , indicating loss of PC1 significantly attenuates responsiveness of the Wnt/β-catenin pathway in osteoblasts.
To examine the role of PC1-dependent Akt activation on transcriptional control of osteoblasts development, we examined Runx2-II promoter activity. In previous studies we have shown that PC1 is coupled to Runx2-II expression, a master regulator in osteoblast function, and that transfection of the Cterminal region of PC1 (PC1-AT) was sufficient to activate the Runx2-II P1 promoter/reporter construct (17) . As shown in Fig. 5C and 5D, we found that either the PI3K inhibitor LY294002 or cotransfection with a dominant negative Akt (dn-Akt) construct resulted in a dose-dependent inhibition of PC1-AT-mediated increase in Runx2-II P1 promoter activity.
Examination of Wnt-related gene expression in Pkd1
Oc-cKO null osteoblasts further supports impairment of Wnt/-catenin signaling. In this regard, we found evidenced for down-regulation of Wnt10b, Axin2, Cox2 and Runx2-II, and up-regulation of the negative regulators sFrp1 and sFrp4 (Fig. 5E ).
DISCUSSION
PC1 is expressed in cells within the osteoblast lineage (18) , and skeletal abnormalities have been reported in Pkd1 mutant mouse models (14, 15, 17, 18) , but from these generalized loss-offunction observations it was not clear if the observed skeletal abnormalities were an indirect consequence of loss of PC1 in multiple tissues or a direct effect of loss of PC1 in osteoblasts. In the present studies, we have addressed this question by using Oc-Cre to conditionally inactivate Pkd1 in mature osteoblasts postnatally. First, we have shown that the heterozygous conditional reduction of Pkd1 in osteoblasts in Oc-Cre;Pkd1 flox/+ results in an osteopenic bone phenotype indistinguishable from the global Pkd1 flox/m1Bei mice. Since Oc-Cre;Pkd1 flox/+ mice had ~25% reduction in Pkd1 expression, whereas Pkd1 flox/m1Bei mice had a 50% reduction, but had identical effects on bone, suggest that loss of Pkd1 function in osteoblasts is responsible for the observed reduction in bone mass in both models. Moreover, the additive effects on the severity of osteopenia in combined conditional deletion of Pkd1 in osteoblasts superimposed on the inactivated Pkd1 m1Bei allele in Oc-Cre;Pkd1 flox/m1Bei (or Pkd1
OccKO ) mice, which resulted in approximately 2-fold greater (~ 14%) reduction in BMD associated with a 75% overall reduction in Pkd1 expression in bone, compared to a 50% reduction in other tissues, indicates a dose-dependent function of Pkd1 in mature osteoblasts.
We purposely did not create Oc-Cre; Pkd1 flox/flox mice, due to the relative inefficiency of the Oc-Cre, which based on the 25% reduction in Pkd1 transcripts observed in Oc-Cre;Pkd1 flox/+ mice may have only reduced expression in Oc-Cre; Pkd1 flox/flox mice to levels similar to the heterozygous Pkd1 flox/m1Bei mice (e.g., 50%). So, to achieve greater reduction in Pkd1 expression in osteoblasts (e.g., ~75%), we created Oc-Cre; Pkd1 flox/m1Bei mice. It is of note that the magnitude of bone loss in Pkd1
Oc-cKO mice is comparable to the 16% reduction in BMD found in Lrp5 null mice (34), a receptor known to have important anabolic osteoblastmediated functions in bone through activation of canonical Wnt signaling pathways and exceeds bone loss observed in oophorectomized mice (which is typically <10%) (35) . Since Pkd1
Oc-cKO had no demonstrable extraskeletal phenotypes and loss of Pkd1 was greatest in bone, these findings are most consistent with a direct role of PC1 to regulate osteoblast function. Evidence for impaired osteoblastic function in Pkd1
Oc-cko null mice is evident from both in vivo and ex vivo analysis. Bone from Pkd1
Oc-cko null mice displayed decreased MAR, MS/BS, BFR, and reduced expression of osteoblastic markers, including the Runx2-II isoform, which regulates osteoblast development and function.
Ex vivo assessment of primary osteoblasts isolated confirmed an intrinsic impairment of osteoblast maturation as well as identified increased proliferation, which are typically inversely related (36) . A feature of ADPKD renal cells is increased proliferation rate as well as impaired differentiation of epithelial cells (37); our findings suggest that this phenotypic switch may also occur in osteoblasts. Indeed, the Pkd1
Oc-cKO null osteoblasts showed a greater proliferation rate as well as impaired osteoblastic differentiation and maturation. Since others have shown that the response of the renal epithelium to acquired loss of Pkd1 is determined by the developmental state of the organ (38) , our data showing a defect in osteoblast maturation in remodeling bone raises the possibility that Pkd1 may also play a role in the embryogenesis of bone. Osteoblasts and adipocytes undergo renewal from bone marrow derived precursors and ratio of osteoblasts and adipocytes appear to be reciprocally controlled in response to physiological stimuli and aging (39) . We also found an inverse dose relationship between Pkd1 expression and adipogenesis marker expression in the Pkd1
Oc-cKO osteoblast cultures compared to the control. In agreement with this in vitro data, our in vivo study also showed strong evidence for lipid droplet accumulation in the bone marrow of
Pkd1
Oc-cKO mice compared with the control mice via Oil Red O and Osmium staining. This phenomenon was also supported an enhanced expression of inflammatory mediators such as IFN and Alox15 (40, 41) , which produced by adipose tissues strongly suppress osteoblastogenesis. The findings of increased fat cells in bone marrow of Pkd1
Oc-cKO mice and impaired development of osteoblast cultures derived from Pkd1
Oc-cKO mice suggest that Pkd1 deficiency may lead to impaired differentiation of mesenchymal stem cells into osteoblasts and enhanced differentiation into adipocytes.
Since Oc-Cre mediated deletion of Pkd1 in osteoblasts would carry forward to the terminal differentiated osteocytes, we cannot exclude a possible role of the osteocyte in the bone phenotype in Pkd1
Oc-cko null mice. In addition to being expressed throughout the osteoblastic lineage during embryogenesis and in postnatal bone, Pkd1 is also expressed in chondrocytes (6) . Consequently, the more severe skeletal abnormalities in global Pkd1 null compared to Pkd1
Oc-cKO mice could be due to PC1 regulation of osteoblast differentiation or chondrocyte function during development or to systemic effects caused by the presence of polycystic kidneys (6, 7) . Additional studies that ablate Pkd1 in earlier in the osteoblast lineage during embryogenesis or later in osteocytes, as well in mature and immature chondrocytes, will be needed to establish a direct role of PC1 in skeletal development and to establish the respective contributions of Pkd1 function in pre-osteoblasts, osteoblasts, osteocytes and chondrocytes.
We previously demonstrated that PC1 selectively regulates Runx2-II P1 promoter activity in osteoblasts through an intracellular calcium pathway linked to nuclear factor I family and AP-1 transcription factors (17) . The PC1 regulates a variety of signal transduction pathways in renal epithelial cells, including Akt1 and GSK3 (26) (27) (28) , which are also important regulators of bone mass (42,43). The present studies indicate that Pkd1 also regulates PI3K-Akt-GSK3 signaling in osteoblasts, and that this pathway is upstream of Runx2. The decline in Akt-GSK3--catenin signaling in osteoblasts from Pkd1
Oc-cko null mice and the finding that PC1-PI3K-Akt signaling regulates Runx2-II P1 promoter activity, suggests that this may represent another Pkd1-dependent pathway regulating osteoblasts function. The interactions between Wnt and Pkd1 dependent signaling pathways, however, are complex, and fur-ther studies will be needed to define the mechanism whereby loss of polycystin 1 results in decreased -catenin activity.
The broader role of PC1 in regulating bone physiology is not revealed by our studies. There is no known ligand for PC. Polycystin potentially functions as a mechanosensor, a chemosensor, or as a sensor of cell-cell or cell-matrix interactions (44,45). PC1 colocalizes to the primary cilium (46) , which is also present in osteoblasts, osteocytes and chondrocytes (47, 48) . Also cleavage of PC1 at the G protein-coupled receptor proteolytic site (GPS) upstream of the first TM segment may be required for bioactivity (49) , suggesting that PC1 may be constitutively active. Although the precise activator in bone remains to be defined, PC1 presence or its ability to sense environmental cues during bone remodeling may allow it to function as a "hub" or a common connection point that permits cells in the osteoblast lineage to sense diverse environmental signals during skeletal development and translate these into multiple signaling pathways required for maintenance of bone mass.
In contrast to the role of Pkd1 in mouse bone, a PC1-dependent bone phenotype has not been reported in humans with ADPKD, who have superimposed renal osteodystrophy. It may yet be possible to detect small, clinically unapparent reductions of bone density in humans heterozygous for PKD1 mutations prior to developing kidney failure. In addition, there are some very interesting but rare families with early onset of polycystic kidney disease in newborns that are associated with severe skeletal malformations, similar to those observed in mice with homozygous Pkd1 mutations, suggesting that broadly disrupting both alleles in osteoblasts /osteocytes (analogous to the Pkd1 null mouse as opposed to random second hits in ADPKD) might cause clinically apparent bone disease in humans (12, 50) .
In conclusion, the finding that selective reduction of Pkd1 in osteoblasts results in osteopenia defines a new signaling paradigm in bone that has the potential expand our understanding of how bone senses environmental signals maintaining bone mass as well as regulating osteoblast growth and development. The further study of polycystin function in bone could provide a variety of new insights, ranging from new mechanosensing mechanisms potentially involving primary cilium to identifying a moleuclar target for the development of pharmacological approaches to increased bone mass in osteopenic disorders.
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The abbreviations used are: ADPKD, autosomal dominant polycystic kidney disease; PKD1 or Pkd1, polycystic kidney disease gene 1; PKD2 or Pkd2, polycystic kidney disease gene 2; PC1, polycystin 1; PC2, polycystin 2; Runx2, Runt-related transcription factor 2; BMD, bone mineral density; CT, microcomputed tomography; BV/TV, bone volume/total volume; Ct.Th., cortical bone thickness. Oc-cko mice, indicating an additive effect of both global and conditional Pkd1 deficiency to impair osteoblast-mediated bone formation. Representative images of the distal tibia-fibula junction sections from 16-week-old mice for each genotype showed progressively reductions in the distance between two calcein double-labeling (Scale bars, 20 µm). C, Oil Red O staining of decalcified femur sections. Representative images of femoral bone marrow showed that the number of adipocytes and fat droplets were greater in 18-weekold Pkd1
Oc-cko mice compared with age-matched control mice. Scale bars, 100 µm and 500 µm. D, Osmium tetroxide (OsO4) staining of decalcified tibias by CT analyses. Qualitatively, the images of osmium staining (White or Red area) were much higher in the proximal tibia from 18-week-old Pkd1
Oc-cko mice compared with age-matched control mice. Quantification of fat cells number and volume were also performed as described in 
